Literature DB >> 23474125

Antibodies to citrullinated peptides and risk of coronary heart disease.

Geraldine Cambridge1, Jayshree Acharya, Jackie A Cooper, Jonathan C Edwards, Steve E Humphries.   

Abstract

OBJECTIVE: Increased cardiovascular risk has been associated with high levels of serum antibodies to citrullinated proteins (ACPA) in patients with rheumatoid arthritis (RA). Citrullination is part of many chronic inflammatory processes and we therefore investigated whether ACPA might be associated with coronary artery disease, in the absence of RA.
METHODS: To maximize the potential predictive value of this retrospective study we included sera from a cohort of 3052 healthy male individuals, subsequently followed for the development of coronary artery disease, and documented for other disease risk factors. With each case event (myocardial infarction; n = 144), 2 matched controls were assigned.
RESULTS: We found 10.4% of cases were ACPA positive compared to 3.8% of controls (odds ratio (95% CI) = 3.26 (1.36-7.80), p = 0.008), remaining significant after adjustment for classical risk factors including smoking and CRP (4.23 (1.22-14.61) p = 0.02).
CONCLUSION: The genesis and fine specificity of ACPA in patients with atherosclerosis, in the absence of Rheumatoid arthritis, may prove worthy of further investigation.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23474125     DOI: 10.1016/j.atherosclerosis.2013.02.009

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  20 in total

Review 1.  [Long-term glucocorticoid therapy : Is there a safe dosage?].

Authors:  C Strehl; F Buttgereit
Journal:  Internist (Berl)       Date:  2016-09       Impact factor: 0.743

Review 2.  Autoimmunity, inflammation, and dysbiosis mutually govern the transition from the preclinical to the clinical stage of rheumatoid arthritis.

Authors:  Alexander Kalinkovich; Gulzan Gabdulina; Gregory Livshits
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

Review 3.  Is preclinical autoimmunity benign?: The case of cardiovascular disease.

Authors:  Darcy S Majka; Rowland W Chang
Journal:  Rheum Dis Clin North Am       Date:  2014-09-17       Impact factor: 2.670

Review 4.  Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications.

Authors:  Bryant R England; Geoffrey M Thiele; Daniel R Anderson; Ted R Mikuls
Journal:  BMJ       Date:  2018-04-23

Review 5.  Cardiovascular Diseases and Periodontitis.

Authors:  Peter Riis Hansen; Palle Holmstrup
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 6.  Vascular calcium signalling and ageing.

Authors:  Osama F Harraz; Lars Jørn Jensen
Journal:  J Physiol       Date:  2021-11-21       Impact factor: 6.228

Review 7.  Atherosclerosis in Rheumatoid Arthritis: Promoters and Opponents.

Authors:  Federico Carbone; Aldo Bonaventura; Luca Liberale; Sabrina Paolino; Francesco Torre; Franco Dallegri; Fabrizio Montecucco; Maurizio Cutolo
Journal:  Clin Rev Allergy Immunol       Date:  2020-02       Impact factor: 8.667

Review 8.  Atherosclerosis in rheumatoid arthritis: is it all about inflammation?

Authors:  Sarah Skeoch; Ian N Bruce
Journal:  Nat Rev Rheumatol       Date:  2015-03-31       Impact factor: 20.543

9.  Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis.

Authors:  Kim L L Habets; Leendert A Trouw; E W Nivine Levarht; Suzanne J A Korporaal; Petra A M Habets; Philip de Groot; Tom W J Huizinga; René E M Toes
Journal:  Arthritis Res Ther       Date:  2015-08-24       Impact factor: 5.156

10.  Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study.

Authors:  Gunter Assmann; Klara Shihadeh; Viola Poeschel; Niels Murawski; Jutta Conigliarou; Mei Fang Ong; Michael Pfreundschuh
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.